Medicine and Dentistry
Breast Cancer
100%
Patient
72%
Therapeutic Procedure
33%
Malignant Neoplasm
23%
Hormone Therapy
23%
Neoplasm
22%
Diseases
22%
Woman
21%
Combination Therapy
19%
Inpatient
17%
Recurrent Disease
14%
Estrogen Receptor
13%
Gene
13%
Triple Negative Breast Cancer
12%
Age
12%
Metastatic Breast Cancer
11%
Breast
9%
Hormone Receptor
8%
BRCA1
8%
Diagnosis
7%
Cancer
7%
Single Nucleotide Polymorphism
7%
Homologous Recombination
7%
Tamoxifen
7%
Overall Survival
7%
Chemotherapy
7%
Association
6%
COVID-19
6%
Cancer Risk
6%
Eribulin
6%
Transforming Growth Factor
6%
Development
6%
Trastuzumab
6%
Adiponectin
6%
Ovarian Cancer
5%
Behcet Disease
5%
Elacestrant
5%
Progression Free Survival
5%
Biological Marker
5%
Assessment
5%
Hazard Ratio
5%
Serum
5%
Gamma Urogastrone
5%
Survival
5%
Receptor
5%
Hispanic
5%
Epidermal Growth Factor Receptor 2
5%
Toxicity
5%
Cohort Analysis
5%
Cancer Growth
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
54%
Neoplasm
16%
Malignant Neoplasm
15%
Metastatic Breast Cancer
13%
Diseases
12%
Chemotherapy
11%
Clinical Trial
10%
Trastuzumab
9%
Recurrent Disease
9%
Paclitaxel
8%
Capecitabine
8%
Cancer Risk
8%
Toxicity
7%
Leptin
7%
Lapatinib
6%
Hormone Receptor
5%
Gamma Urogastrone
5%
Elacestrant
5%
Sorafenib
5%
Tamoxifen
5%
Progression Free Survival
5%
Anthracycline
5%
Triple Negative Breast Cancer
5%
Solid Malignant Neoplasm
5%
Receptor
5%
Overall Survival
5%
Biochemistry, Genetics and Molecular Biology
Nested Gene
19%
Association
16%
Adiponectin
13%
Mutation
11%
Single-Nucleotide Polymorphism
10%
Transforming Growth Factor
9%
BRCA1
8%
Development
8%
Age
7%
Allele
6%
Growth
6%
Body Mass
5%
Cancer Cell
5%
Case-Control Study
5%
Homologous Recombination
5%
Weight
5%
